Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Limertinib followed by combination chemotherapy for EGFR-mutant advanced NSCLC
ChiCTR2600129771Phase 2Not yet recruiting
- Sponsor
- Meishan Tumor Hospital
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of limertinib in non-small cell lung cancer (NSCLC), sponsored by Meishan Tumor Hospital. Primary endpoint: Progression-free survival. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
limertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600129771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129771.